VACCITECH PLC (VACC) Stock Price, Quote, News and Overview
NASDAQ:VACC - Nasdaq - US91864C1071 - ADR - Currency: USD
VACC Quote, Performance and Key Statistics
5
+0.51 (+11.36%)
The current stock price of VACC is 5 USD. In the past month the price increased by 47.06%. In the past year, price increased by 116.45%.
VACC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.97 | 326.55B | ||
| AMGN | AMGEN INC | 12.81 | 142.94B | ||
| GILD | GILEAD SCIENCES INC | 12.52 | 120.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 109.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.91 | 56.98B | ||
| ARGX | ARGENX SE - ADR | 93.64 | 33.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.67B | ||
| ONC | BEIGENE LTD-ADR | 5.79 | 25.01B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
| NTRA | NATERA INC | N/A | 20.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
| BIIB | BIOGEN INC | 7.47 | 17.32B |
Related stock screener links
About VACC
Company Profile
Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmunity. The company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The company has a pipeline of both clinical and preclinical-stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB); VTP-200 for the treatment of human papilloma virus infection (HPV); VTP-850 for the treatment of prostate cancer; VTP-600 for the treatment of non-small cell lung cancer (NSCLC); VTP-1000 for the treatment of celiac disease, and VTP-1100 for the treatment of HPV-associated cancers. Its prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles, and VTP-500 for the prevention of Middle East respiratory syndrome (MERS).
Company Info
VACCITECH PLC
Unit 6-10, Zeus Building, Rutherford Avenue, Harwell
Didcot OXFORDSHIRE OX4 4GE GB
CEO: William Enright
Employees: 107
Phone: 4401865818808.0
VACCITECH PLC / VACC FAQ
What is the stock price of VACCITECH PLC today?
The current stock price of VACC is 5 USD. The price increased by 11.36% in the last trading session.
What is the ticker symbol for VACCITECH PLC stock?
The exchange symbol of VACCITECH PLC is VACC and it is listed on the Nasdaq exchange.
On which exchange is VACC stock listed?
VACC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VACCITECH PLC stock?
11 analysts have analysed VACC and the average price target is 9.5 USD. This implies a price increase of 89.97% is expected in the next year compared to the current price of 5. Check the VACCITECH PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VACCITECH PLC worth?
VACCITECH PLC (VACC) has a market capitalization of 192.73M USD. This makes VACC a Micro Cap stock.
How many employees does VACCITECH PLC have?
VACCITECH PLC (VACC) currently has 107 employees.
What are the support and resistance levels for VACCITECH PLC (VACC) stock?
VACCITECH PLC (VACC) has a support level at 3.74. Check the full technical report for a detailed analysis of VACC support and resistance levels.
Is VACCITECH PLC (VACC) expected to grow?
The Revenue of VACCITECH PLC (VACC) is expected to decline by -95.74% in the next year. Check the estimates tab for more information on the VACC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VACCITECH PLC (VACC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VACC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VACC, evaluating the profitability, health, valuation and growth aspects
- VACCITECH PLC (VACC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VACCITECH PLC (VACC) Sales and EPS estimates to see what analysts future expectations are.
- VACCITECH PLC (VACC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VACCITECH PLC (VACC) Insider and Institutional Ownership to learn about the owners and their transactions.
- VACCITECH PLC (VACC) Stock Chart to make your own analysis
- VACCITECH PLC (VACC) Latest news and press-releases to stay up to date.
Does VACCITECH PLC (VACC) stock pay dividends?
VACC does not pay a dividend.
What is the Price/Earnings (PE) ratio of VACCITECH PLC (VACC)?
VACCITECH PLC (VACC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.45).
VACC Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to VACC. When comparing the yearly performance of all stocks, VACC is one of the better performing stocks in the market, outperforming 99.36% of all stocks.
VACC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VACC. While VACC has a great health rating, there are worries on its profitability.
VACC Financial Highlights
Over the last trailing twelve months VACC reported a non-GAAP Earnings per Share(EPS) of -1.45. The EPS decreased by -4723.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.32% | ||
| ROE | -25.29% | ||
| Debt/Equity | 0 |
VACC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to VACC. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -1733.53% and a revenue growth -95.74% for VACC